These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 33106584)

  • 1. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    Lozano R; Castro E; Aragón IM; Cendón Y; Cattrini C; López-Casas PP; Olmos D
    Br J Cancer; 2021 Feb; 124(3):552-563. PubMed ID: 33106584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
    N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitors in Prostate Cancer.
    Grewal K; Grewal K; Tabbara IA
    Anticancer Res; 2021 Feb; 41(2):551-556. PubMed ID: 33517260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
    Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
    Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of DNA damage repair alterations for the management of prostate cancer.
    Lozano R; Olmos D; Castro E
    Curr Opin Urol; 2022 May; 32(3):302-310. PubMed ID: 35266912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    Siebert AL; Szymaniak BM; Numan Y; Morgans AK
    Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-emergent neuroendocrine prostate cancer with a germline
    Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
    Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    Salaün H; Saint-Ghislain M; Bellesoeur A; Beuzeboc P; Neuzillet C; Diéras V; Stern MH; Rodrigues M
    Bull Cancer; 2022 Jan; 109(1):76-82. PubMed ID: 34799081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 13. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.
    Glade Bender JL; Pinkney K; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    Oncologist; 2024 Jul; 29(7):638-e952. PubMed ID: 38815151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
    Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
    Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
    Ghose A; Moschetta M; Pappas-Gogos G; Sheriff M; Boussios S
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.